Management of Chronic Lymphocytic Leukemia in the Elderly.

ABSTRACT:

Background

Because chronic lymphocytic leukemia (CLL) typically follows an indolent course, many patients do not need to initiate therapy until they reach a relatively advanced age, when frailty and reduced organ function can make some of the standard treatments difficult to tolerate and less effective. However, recent advances in the understanding of CLL biology and the approval of agents in novel treatment classes have offered significant advances in the management of the disease.

Methods

The author reviewed current treatment goals in CLL management, including issues surrounding complete remission (CR) and minimal residual disease (MRD); the findings of trials of treatments from novel drug classes, primarily kinase inhibitors and monoclonal antibodies; and current strategi

SUBMITTER: Barrientos JC 

PROVIDER: S-EPMC4763599 | biostudies-literature | 2015 Oct

REPOSITORIES: biostudies-literature